Clinical trials: Severe Respiratory Distress Syndrome
COVID-19 Acute Respiratory Distress Syndrome
Efficacy of Respiratory Physiotherapy on Severe ICU-admitted COVID-19 Patients.
COVID-19 is an infectious disease caused by SARS-CoV2 virus. COVID-19 patients can develop a severe disease that can lead to hypoxic respiratory failure and acute respiratory distress syndrome (ARDS).
- Trial name
- NCT05067907
- Testing
- Early physiotherapy
- Where
- 4 sites in Italy
- Volunteers
- 244 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Corona Virus Infection, Acute Respiratory Distress Syndrome
Losartan for Patients With COVID-19 Not Requiring Hospitalization
This is a multi-center, double-blinded study of COVID-19 infected patients randomized 1:1 to daily losartan or placebo for 10 days or treatment failure (hospital admission).
- Conditions
- Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection
- Trial name
- NCT04311177
- Testing
- Losartan
- Where
- 4 sites in United States
- Volunteers
- 117 people
- Sponsor
- University of Minnesota
Multi-organ Failure After Severe Trauma
Metabolic Reprogramming in Renal Tubular Cells in Acute Kidney Injury Following Severe Trauma
Severe trauma remains the leading cause of death in people under 50, and is associated with high morbidity, including severe disability, with a substantial socio-economic impact.
- Trial name
- METAKIT (NCT06167512)
- Where
- 2 sites in France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Moderate to Severe Acute Respiratory Distress Syndrome
Effects on Biotrauma of NMBAs and PP Association During ARDS
The improved survival of patients with acute respiratory distress syndrome (ARDS) over the last decades is related to the use of so-called "protective" mechanical ventilation.
- Trial name
- CURA-PRONE (NCT06212492)
- Testing
- NMBAs, Prone positioning
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Prone Position, Severe Acute Respiratory Syndrome Coronavirus 2
Evaluation of Sedation in COVID-19 ARDS
This study focuses on the evaluation of various factors repeatedly discussed in relation to the impaired sedation of intubated ventilated COVID-19 patients.
- Conditions
- Prone Position, Severe Acute Respiratory Syndrome Coronavirus 2, Hypnotics and Sedatives, Pulmonary Ventilation
- Trial name
- NCT04667936
- Testing
- Treatment group
- Where
- Germany
- Volunteers
- 114 people
- Sponsor
- Goethe University
Median Nerve Entrapement
Large Scale ICU Data Sharing for 1000 Critically Ill Patients With Severe Acute Respiratory Distress Syndrome Coronavirus (SARS.COV19) in Three Distinct Isolation Centers
Cohort study of patients with severe respiratory distress syndrome coronavirus2 in three different isolation hospitals recording data about outcome.
- Trial name
- NCT04779268
- Where
- Egypt
- Volunteers
- 1,000 people
- Sponsor
- Minia University
Acute Respiratory Distress Syndrome (ARDS)
Multicentric, Randomized Study to Assess Safety and Efficacy of Centhaquine in Patients With ARDS
Acute respiratory distress syndrome (ARDS) is a life-threatening condition with a diffuse, inflammatory form of lung injury, causing pulmonary infiltration and respiratory failure leading to poor oxygenation.
- Trial name
- NCT05241067
- Testing
- Normal Saline, Centhaquine
- Volunteers
- 80 people
- Sponsor
- Pharmazz, Inc.
Acute Respiratory Distress Syndrome, Ventilator-Induced Lung Injury
Impact of the Depth of Neuromuscular Blockade on Respiratory Mechanics in Moderate to Severe ARDS Patients
Neuromuscular blockade (NMB) is proposed in patients with moderate to severe acute respiratory distress syndrome (ARDS). The supposed benefit of these muscle relaxants could be partly linked to their effects on respiratory…
- Trial name
- NCT05697666
- Testing
- Modulation of the depth of the neuromuscular blockade
- Where
- France
- Volunteers
- 33 people
- Sponsor
- Centre Hospitalier de Saint-Brieuc
COVID-19
Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients
Study of ANA001 in Moderate and Severe COVID-19 Patients
- Trial name
- NCT04603924
- Testing
- Niclosamide
- Where
- 8 sites in United States
- Volunteers
- 49 people
- Sponsor
- NeuroBo Pharmaceuticals Inc.
Respiratory Distress Syndrome, Adult
COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111
To demonstrate the efficacy of VERU-111 in the treatment of SARS-Cov-2 Infection by assessing its effect on the proportion of subjects that are alive without respiratory failure at Day 22.
- Trial name
- NCT04388826
- Testing
- Veru-111
- Where
- 5 sites in United States
- Volunteers
- 39 people
- Sponsor
- Veru Inc.
Coronavirus Disease 2019, Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2
Study of Varespladib in Patients Hospitalized With Severe COVID-19
This is a 2-part, multi-center, randomized, double-blind, placebo-controlled, phase 2 study designed to evaluate the safety, tolerability, and efficacy of oral varespladib, in addition to standard of care, in patients…
- Trial name
- STAIRS (NCT04969991)
- Testing
- Varespladib
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- Ophirex, Inc.
Covid-19, Respiratory Distress Syndrome
Vitamin D Supplementation and Clinical Outcomes in Severe COVID-19 Patients
Single center, open label randomized clinical trial. Study location: tertiary hospital center (University Hospital Split, Croatia).
- Conditions
- Covid-19, Respiratory Distress Syndrome, Vitamin D Deficiency
- Trial name
- NCT05384574
- Testing
- cholecalciferol
- Where
- Croatia
- Volunteers
- 200 people
- Sponsor
- University Hospital of Split
Acute Respiratory Distress Syndrome, Chest Trauma
Serum sRAGE, CC16, and Syndecan-1 as Predictors of ARDS and Mortality After Severe Chest Trauma
This prospective cohort study aims to evaluate whether blood levels of soluble receptor for advanced glycation end products (sRAGE), Club Cell Protein-16 (CC16), and Syndecan-1 measured early after severe chest trauma can predict…
- Trial name
- NCT07774338
- Testing
- No intervention - observational study
- Volunteers
- 85 people
- Sponsor
- Assiut University
Acute Respiratory Distress Syndrome, Infections
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
BTI-203 is a randomized, double-blind, placebo-controlled, multicenter, Phase 2 proof-of-concept (POC) study to evaluate the efficacy and safety of rhu-pGSN plus standard of care (SOC) in subjects with moderate-to-severe ARDS…
- Trial name
- NCT05947955
- Testing
- Rhu-pGSN, normal saline
- Where
- 65 sites in United States, Belgium and 11 more
- Volunteers
- 600 people
- Sponsor
- BioAegis Therapeutics Inc.
Severe Sepsis, Acute Respiratory Distress Syndrome
Efficacy of Bevacizumab in Preventing Acute Respiratory Distress Syndrome (ARDS)
This study aims to test the effectiveness of a single intravenous (IV, through the vein) dose of the study drug, bevacizumab (Avastin), in preventing/reducing the development of Acute Respiratory Distress Syndrome (ARDS), in…
- Trial name
- VEGF-ARDS (NCT01314066)
- Testing
- Bevacizumab
- Where
- United States
- Sponsor
- Weill Medical College of Cornell University
Respiratory Distress Syndrome, Adult
New Lung Ventilation Strategies Guided by Transpulmonary Pressure in VV-ECMO for Severe ARDS
Extracorporeal membrane oxygenation (ECMO) has been widely used in patients with severe acute respiratory distress syndrome (ARDS).
- Trial name
- NCT02439151
- Testing
- New lung ventilation strategy, Conventional ventilation strategy
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Rui Wang
Acute Respiratory Distress Syndrome
Comparison of Different PEEP Strategies in Moderate-to-Severe ARDS Based on Various Bedside Assessment Tools
Many patients admitted to the intensive care unit (ICU) for a severe lung disease called acute respiratory distress syndrome (ARDS) require mechanical ventilation and positive end-expiratory pressure (PEEP) to improve their…
- Trial name
- OPTI-PEEP (NCT07741916)
- Testing
- Ventilation at different levels of PEP including a test involving a gradual decrease in PEP.
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Dyspnea, COVID-19
Two-year Efficacy of Three Exercise Rehabilitation Strategies on Dyspnea in Patients Who Presented With Secondary Respiratory Distress Syndrome Secondary to Severe COVID-19 Pneumonia
Dyspnea is defined by a subjective sensation of respiratory discomfort, the intensity of which varies according to the terrain, the anamnesis and the cause.
- Trial name
- RECOVER_FU (NCT05890560)
- Where
- 4 sites in France
- Volunteers
- 120 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Dyspnea
Effectiveness of an Exercise Re-training Program on Dyspnea in Patients After Acute Respiratory Distress Syndrome Secondary to Severe COVID-19 Pneumonia in Post-ICU
Dyspnea is defined by a subjective sensation of respiratory discomfort, the intensity of which varies according to the terrain, the anamnesis and the cause.
- Trial name
- RECOVER (NCT04569266)
- Testing
- Specific exercise rehabilitation treatment, No specific exercise rehabilitation treatment
- Where
- 3 sites in France
- Volunteers
- 63 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Acute Respiratory Distress Syndrome, Adult
Treatment of Severe Acute Respiratory Distress Syndrome With Allogeneic Bone Marrow-derived Mesenchymal Stromal Cells
This is a multi-center, open-label, non-randomized controlled trial. Patients with viral-induced acute respiratory distress syndrome (ARDS) on extracorporeal membrane oxygenation (ECMO) will be eligible.
- Trial name
- NCT02215811
- Testing
- Mesenchymal stromal cells
- Where
- 2 sites in Sweden
- Volunteers
- 10 people
- Sponsor
- Karolinska University Hospital